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Abstract: Prospective cohort studies significantly contribute to answering specific research questions in
a defined population. Since 2008, the Swiss Transplant Cohort Study (STCS) systematically enrolled
>95 % of all transplant recipients in Switzerland, collecting predefined data at determined time points.
Designed as an open cohort, the STCS has included >3900 patients to date, with a median follow-up
of 2.96 years (IQR 1.44-4.73). This review highlights some relevant findings in the field of transplant-
associated infections gained by the STCS so far. Three key general aspects have crystallized: (i) Well-
run cohort studies are a powerful tool to conduct genetic studies, which are crucially dependent on a
meticulously described phenotype. (ii) Long-term real-life observations are adding a distinct layer of
information that cannot be obtained during randomized studies. (iii) The systemic collection of data,
close interdisciplinary collaboration, and continuous analysis of some key outcome data such as infectious
diseases endpoints can improve patient care.
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Abstract Prospective cohort studies significantly contribute
to answering specific research questions in a defined popula-
tion. Since 2008, the Swiss Transplant Cohort Study (STCS)
systematically enrolled >95 % of all transplant recipients in
Switzerland, collecting predefined data at determined time
points. Designed as an open cohort, the STCS has included
>3900 patients to date, with a median follow-up of 2.96 years
(IQR 1.44–4.73). This review highlights some relevant find-
ings in the field of transplant-associated infections gained by
the STCS so far. Three key general aspects have crystallized:
(i) Well-run cohort studies are a powerful tool to conduct
genetic studies, which are crucially dependent on a
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meticulously described phenotype. (ii) Long-term real-life ob-
servations are adding a distinct layer of information that can-
not be obtained during randomized studies. (iii) The systemic
collection of data, close interdisciplinary collaboration, and
continuous analysis of some key outcome data such as infec-
tious diseases endpoints can improve patient care.
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Introduction
The infectious disease burden after transplantation is one of
the most important factors impacting patient morbidity, mor-
tality, and, ultimately, the success of a transplant program [1].
Challenges in the management and prevention of infectious
complications in transplant recipients, as well as the conse-
quences of infection in the patient and the allograft, are unique
to this population. Knowledge of local epidemiology is key to
guide the care of both the individual transplant recipient and
the implementation of prevention strategies. Long-term con-
sequences of some infections, such as cytomegalovirus
(CMV) infection, have been postulated, but missing long-
term data hampers determination of their role. A particular
pattern of occurrence of infections after transplantation has
been recognized and associated with the net state of immuno-
suppression. The impact of a refined monitoring of immuno-
suppression and improved prevention of infections on this
timeline is unclear. Increasingly, the role of host factors such
as genetic polymorphisms is intensely explored, but a mean-
ingful analysis is directly linked to the number of patients
under observation as well as the quality of outcome data
available.
The Swiss Transplant Cohort Study (STCS) was founded
with the purpose to establish a tool to tackle some of these
questions. Currently, over 60 research projects embedded in
the STCS are active, from purely epidemiological analyses to
translational studies, as well as randomized trials (http://www.
stcs.ch/research/scientific-projects/). All topics relevant to
transplantation are covered. This review concentrates on the
published results concerning post-transplant infectious com-
plications and focuses on the potential of such a cohort. STCS
results on other aspects related to transplantation will not be
discussed [2–5].
The Features of the STCS
The STCS (www.stcs.ch) prospectively enrolls all transplant
recipients from the six Swiss transplant centers. A modular
concept collects general data such as transplant infectious
endpoints and psychosocial variables, by dedicated teams.
The type of data collected is tailored to the transplanted
organ. Variables are predefined and assembled prospectively
(Table 1). All involved patients provide an informed consent
for the extensive data collection, as well as the sampling of
biological material. By law, a minimal data set is obtained for
each recipient. Since its start in 2008, enrollment has been
>95 %, with currently 4150 (March, 25th, 2015) solid-organ
recipients in the database. Since 2011, patients after allogeneic
stem cell transplantation have been enrolled as well. The
STCS is designed as an open cohort with regular follow-ups
performed every year [6, 7]. Funding is provided by the Swiss
National Science Foundation, the Swiss University Hospitals,
and the five Swiss transplant centers (Basel, Bern, Geneva,
Lausanne, St. Gallen, Zürich).
The studies described below have been performed in the
context of the STCS.
Epidemiological Studies
The impact of enterococcal colonization and infection on re-
cipients was studied in 1234 solid-organ transplant (SOT)
recipients [8•]. Two-hundred fifty-five (20.7 %) patients with
Enterococci were documented, 185 (47.2 %) with an infec-
tion, and 205 (52.3 %) with colonization. Only two isolates
were vancomycin-resistant, reflecting the still favorable anti-
microbial resistance situation in Switzerland. A shift toward
Enterococcus faeciumwas noted, with the latter being respon-
sible for about half of the infections by Enterococci. An im-
portant finding was that whereas enterococcal colonization
was frequent in SOT recipients, progression from colonization
to infection was rare (4/205; 2 %), supporting the restrained
use of antibiotics for colonized patients.
The role of a positive serology for CMVon the incidence of
biopsy-proven graft rejection or graft loss was analyzed in
1414 SOT recipients, including heart (n=97), kidney
(n=917), liver (n=237), and lung (n=163) recipients [9]. A
positive CMV donor or recipient serological constellation
(IgG) predicted a higher incidence of graft rejection after liver
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and lung transplantation. CMV replication in all SOT recipi-
ents was associated with an increased risk for biopsy-proven
graft rejection within 4 weeks after detection. Valganciclovir
prophylaxis delayed but did not prevent graft loss.
The best prevention strategy against CMV in SOT recipi-
ents remains an intensely discussed topic. In particular, the
effect on non-CMV endpoints such as rejection or long-term
graft function remains unclear. The long-term design of the
STCS is well suited to shed some light on this issue. One
thousand two hundred thirty-nine SOT recipients (all organs)
were included in this analysis, in which prophylaxis was com-
pared with a preemptive approach. The main result showed
that the use of a prophylactic approach was associated with
improved graft-failure-free survival after a median of
1.05 years of follow-up (hazard ratio 1.63 for the preemptive
approach [95 % CI 1.01–2.64], p=0.044). This was not due to
the incidence of CMV disease, as both strategies prevented
this complication very efficiently, but potentially to the occur-
rence of asymptomatic CMV replication early after transplant.
The limitations and benefits of a prospective cohort need to be
taken into account when putting these results in a perspective.
While not based on a randomized design, the almost complete
inclusion of all transplanted patients depicts real life scenarios
very precisely [10•].
Studies Using Biological Samples
Patients enrolled in the STCS are regularly sampled during the
first year at 0, 6, and 12 months after transplantation. Plasma,
DNA, and viable cells are available for studies. The strength
of the STCS lies in a very precise description of multiple
phenotypes with prospective collection of pertinent endpoints.
This allows for careful patient selection and the ability to
correlate findings generated in the laboratory with clinical
relevant outcomes. This may form the basis for well-
founded translational hypotheses.
Translational and Genetic Studies
Association of activating killer cell immunoglobulin-like re-
ceptor (KIR) genes with protection from CMV has been pos-
tulated after organ transplantation. This STCS study correlated
KIR genotype and CMV serostatus at the time of transplanta-
tion with rates of CMV viremia in a total of 517 (heart (n=57),
kidney (n=223), liver (n=165), or lung (n=72)) allograft re-
cipients. In CMV-seropositive organ transplant recipients
treated with intense immunosuppression (i.e., depleting proto-
cols), KIR-activating haplotypes were associated with protec-
tion against CMV viremia. These data indicate an important
role for KIR and natural killer (NK) cells in the control of
CMV replication [11•].
Two genetic studies elucidated the role of polymorphisms
of immune mediators. The first explored the role of IFNL3
Table 1 Variables collected for assessment of infectious diseases
events in the Swiss Transplant Cohort Study







• Site not identified
• Bacteremia/fungemia/viremia
• Bone and joints
































Specific pathogens are chosen from a comprehensive list. Resistance
pattern is collected for Enterococcus spp, Staphylococcus aureus
(MRSA), and Gram negative (MDR, ESBL). Type of therapy is indicated
(antifungal, antiviral, antibacterial)
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and IFNL4, the genes encoding interferon λ3 and interferon
λ4, on the incidence of CMVinfection after transplantation. A
polymorphism involved in the clearance of hepatitis C virus
infection was investigated in 840 SOT recipients, of whom
44 % received antiviral prophylaxis. Homozygosity for the
minor (−G/−G) allele was associated with a higher incidence
of CMV replication in patients followed by a preemptive ap-
proach, in contrast to those under prophylaxis. This associa-
tion remained valid in multivariate competing risk regression
analysis [12].
The second study looking at interleukin-1 beta and β-
defensin-1 polymorphisms among 1101 SOT recipients
showed that single-nucleotide polymorphisms of the encoding
genes were associated with mold colonization and proven/
probable mold infections. A potential mechanism was pro-
posed by showing a reduced secretion of IL-1 β and TNF-α
upon stimulation with Aspergillus in peripheral blood mono-
nuclear cells harboring two copies of the rare allele [13••].
Non-Scientific Benefits
Less well studied and more difficult to prove are potential
non-scientific benefits of a systematic collection of outcome
variables in cohort studies. The impact on routine clinical care
in the STCS setting can be seen on many levels including the
multidisciplinary collaboration required to decide on defini-
tions and the auditing process that compels each center to
revise its own protocols. If needed, a national consensus can
be reached, as demonstrated by the recently published Swiss
guidelines on vaccination of SOT recipients reflecting local
custom [14]. The possibility to compare incidence rates for
any infection between centers should not be used to discredit,
but rather to detect uncommon patterns enabling a rapid re-
sponse if necessary. The regular exchange in the Transplant
Infectious Disease group fosters trust, allowing discussion of
difficult cases with a low threshold, ultimately resulting in a
benefit for the patients—as does the often challenging ques-
tions about potential infectious disease risk of possible donors.
All centers receive a center-specific report with relevant out-
come information, which can be used for internal quality
control.
Challenges and Limitations
The STCS is a high-maintenance cohort. The data set collect-
ed is extensive and needs regular auditing to ensure a contin-
uously high quality. The workload can also be substantial for
clinicians and requires ongoing motivation and support. For
many specific research questions, the cohort can flag patients
of interest, but an additional chart review is often necessary.
Sampling is not associated with specific events. Despite these
challenges, the benefits are many, resulting in a high accep-
tance and support in all centers.
Conclusions
Awell-designed high-quality prospective cohort study can be
a powerful scientific tool for carefully chosen research ques-
tions. The limitations of the cohort design need be acknowl-
edged, but it is crucial to realize that randomized trials have
their shortfalls as well. The two concepts should not be played
off against each other, but rather seen as complementary. Re-
cent large trials have indeed merged the two designs, the con-
cept of Bthe randomized registry trial^ as recently discussed, a
very promising trend [15, 16]. The STCS has already been
successful in producing relevant published results concerning
genetic or immunological markers and their relation to clinical
endpoints. A new field of research may be seen exploring the
non-scientific benefits of cohort studies resulting in improved
patient care.
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